Nese Ersoz Gulcelik

Nese Ersoz Gulcelik

Auto-generated profile, based on publicly available information

Nese Ersoz Gulcelik

Department of Endocrinology and Metabolic Diseases, Gulhane Research and Training Hospital, University of Health Sciences, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 May 2011 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
NGN. E. Gulcelik
N. E. Gulcelik
MBM. Bayraktar
M. Bayraktar
OCO. Caglar
O. Caglar
MAM. Alpaslan
M. Alpaslan
JKJ. Karakaya
J. Karakaya
Aim: Type 2 diabetic patients have an increased incidence of hip fracture. In this study, we aimed to evaluate the mortality rate after hip fracture and determine the predictors of mortality in diabetic patients. Methods: 356 patients who sustained a hip fracture between January 1997 and June 2008 were retrospectively reviewed for the study. Of the eligible 230 patients, 69 had type 2 diabetes. Each of these patients’ medical and nursing notes were reviewed to ascertain additional information, including patient demographic factors, prior co-morbidities, fracture type, length of post-fracture stay and post-operative complications, the presence and duration of diabetes, glucose levels, HbA1c levels, albumin and hemoglobin levels. Results: 148 women (64.3%) and 82 men (35.7%) were included in the study. The mean age of the study group was 76.1±10.4 years. The mean age for diabetics was 76.1±12.0 years and was 75.1±9.4 years for non-diabetics (p=0.343). Diabetic patients with hip fracture had a higher risk of mortality than the non-diabetic patients. One year survival probabilities of diabetic and non-diabetic patients were respectively 68.0% and 87.3% (p=0.033). In diabetic patients with a hip fracture, predictors of mortality were advanced age, the presence of postoperative complications and elevated HbA1c levels. Conclusions: Diabetic patients have an increased risk of mortality after hip fracture. The medical care in the post-operative period, including glycemic control and postoperative complications, should be optimized in diabetic patients suffering from hip fracture in order to decrease mortality in these patients.

1 January 2009 in European Journal of Endocrinology
Verified
Journal Article
Closed access
NGNese Ersoz Gulcelik
Nese Ersoz Gulcelik
JKJale Karakaya
Jale Karakaya
AGArzu Gedik
Arzu Gedik
AUAydan Usman
Aydan Usman
AGAlper Gurlek
Alper Gurlek
Objective: Vaspin is a novel adipokine that has insulin sensitizing effects. The association between serum vaspin levels and diabetic complications is unknown. In this study, we aimed to evaluate serum vaspin levels as related to glycemic status and the presence of complications in a group of type 2 diabetic women.Materials and methods: We evaluated 37 type 2 diabetic female patients and 37 control female subjects who were matched for age and body-mass index. Anthropometric measurements, insulin, hemoglobin A1c (HbA1c), C-reactive protein, and serum vaspin levels were measured in each participant. Furthermore, the patients were evaluated for diabetic neuropathy, nephropathy, and retinopathy.Results: In diabetic patients, serum vaspin levels correlated positively with HbA1c and correlated negatively with insulin levels and homeostasis model assessment. The patients with HbA1c levels ≤7% had lower levels of serum vaspin than patients with HbA1c levels >7% (0.11±0.06 ng/ml versus 0.20±0.09 ng/ml,P<0.05). In patients with neuropathy, retinopathy, and nephropathy, serum vaspin levels were lower than in patients without neuropathy (0.10±0.07 ng/ml versus 0.17±0.09 ng/ml,P=0.041), retinopathy (0.11±0.06 ng/ml versus 0.18±0.09 ng/ml,P=0.019), and nephropathy, (0.11±0.05 ng/ml versus 0.18±0.09 ng/ml,P=0.02). Diabetic patients receiving metformin therapy had lower vaspin levels than patients not receiving metformin.Conclusion: Diabetic women with good glycemic control have lower levels of vaspin than those with poor glycemic control. However, presence of microvascular complications is also associated with low vaspin levels. In order to use serum vaspin levels as a marker, evaluating patients for complications and medications interfering with serum vaspin levels seems appropriate.

19 March 2009 in Langenbeck's Archives of Surgery
Verified
Journal Article
Closed access
PDF file
BKBekir Kuru
Bekir Kuru
NGNese Ersoz Gulcelik
Nese Ersoz Gulcelik
MGMehmet Ali Gulcelik
Mehmet Ali Gulcelik
HDHalil Dincer
Halil Dincer

1 May 2005 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
NGN. E. Gulcelik
N. E. Gulcelik
EKE. Kaya
E. Kaya
BDB. Demirbas
B. Demirbas
CCC. Culha
C. Culha
GKG. Koc
G. Koc
YAY. Aral
Y. Aral

25 September 2009 in Endocrine
Verified
Journal Article
Closed access
PDF file
NGNese Ersoz Gulcelik
Nese Ersoz Gulcelik
AUAydan Usman
Aydan Usman
AGAlper Alper Gürlek
Alper Alper Gürlek

8 April 2011 in Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
NZN Dilara Zeybek
N Dilara Zeybek
NGNese Ersoz Gulcelik
Nese Ersoz Gulcelik
FKF Figen Kaymaz
F Figen Kaymaz
CSCan Sarisozen
Can Sarisozen
IVImran Vural
Imran Vural
EAEsin Asan
Esin Asan
Statins show antiproliferative activity in various cancer cells. The aim of this study was to evaluate the effects of rosuvastatin treatment on papillary thyroid carcinoma. The papillary thyroid carcinoma (B-CPAP) and normal (Nthy-ori 3-1) thyroid cell lines were treated with rosuvastatin at 12.5, 18.5, 25, 50, 100, and 200 μM concentrations. After 48 and 72 h of rosuvastatin treatment, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, Ki-67 immunolabeling, FACS analysis, electron microscopy, caspase-3, and terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) analysis were performed. Decreased cell viability and G1 phase arrest were detected in papillary thyroid cell line treated with rosuvastatin. Positive immunoreactivity of Ki-67 and dose-dependent increase in S phase on Nthy-ori 3-1 cells were also detected. B-CPAP cells showed intense vacuolisation and autophagosomes with low concentrations and 48 h incubations, while Nthy-ori 3-1 cells showed these changes at higher concentrations. A decrease in the percentage of cells showing autophagy was determined with increasing concentrations of rosuvastatin in B-CPAP cells. Rosuvastatin treatment also caused a dose- and time-dependent increase in caspase-3 activity and apoptotic index by TUNEL assay in B-CPAP cells compared with the Nthy-ori 3-1 cells. Apoptotic cells with nuclear condensation and fragmentation were observed in B-CPAP cell line. Rosuvastatin induced autophagic changes in B-CPAP papillary thyroid cancer cells in lower doses and caused a shift from autophagy to apoptosis. Rosuvastatin may be an alternative treatment for refractory papillary thyroid cancer. Further in vivo studies are necessary to clarify the effects of rosuvastatin in papillary thyroid carcinoma and the clinical implications of rosuvastatin treatment.